How to Manage Resistant Hypertension Min Su Hyon, MD

Similar documents
RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Combination Therapy for Hypertension

Management of Resistant Hypertension in Diabetes

hypertension Head of prevention and control of CVD disease office Ministry of heath

Management of High Blood Pressure in Adults

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Secondary Hypertension: A Real World Approach

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Genetic factors. A number of genetic factors or interactions between genes play a major role in essential hypertension.

Approach to patient with hypertension. Dr. Amitesh Aggarwal

Categories of HTN. Overview of Hypertension. Types of Hypertension

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertension (JNC-8)

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

major public health burden

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

5.2 Key priorities for implementation

Getting BP to goal: Virginia L. Hood MB.BS, MPH, FACP

Hypertension Management Controversies in the Elderly Patient

Hypertension in the very old. Objectives: Clinical Perspective

Hypertension Update Background

Management of Hypertension

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Jared Moore, MD, FACP

Hypertension Update. Aaron J. Friedberg, MD

ADVANCES IN MANAGEMENT OF HYPERTENSION

Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study

What s all the Fuss?

Hypertension Management - Summary


Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Preventing and Treating High Blood Pressure

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

STANDARD treatment algorithm mmHg

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Managing Hypertension in 2016

Hypertension. Most important public health problem in developed countries

Prevention of Heart Failure: What s New with Hypertension

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure

Byvalson. (nebivolol, valsartan) New Product Slideshow

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

ADVANCES IN MANAGEMENT OF HYPERTENSION

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

By Prof. Khaled El-Rabat

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Hypertension Pharmacotherapy: A Practical Approach

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

DIRECT RENIN INHIBITOR (DRI) EFFECT ON GFR AND USE IN RENAL ARTERY STENOSIS SCREENING

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

Difficult to Treat Hypertension

Summary/Key Points Introduction

The Failing Heart in Primary Care

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Diabetes and Hypertension

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

High blood pressure (Hypertension)

Hypertension Update Clinical Controversies Regarding Age and Race

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Hypertension and Cholesterol in the Elderly

RESISTANT HYPERTENSION

Hypertension in Paediatric Haematology/Oncology

Strategies for Managing Hypertension

Cardiac Pathophysiology

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

SAURIN GANDHI, AZCOM Evidence-Based Guideline for the Management of High Blood Pressure in Adults (JNC 8)

What in the World is Functional Medicine?

Antihypertensive Agents

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Akash Ghai MD, FACC February 27, No Disclosures

Section 3, Lecture 2

The Evolution To Treatment Of Hypertension With Advanced Formulation

Modern Management of Hypertension

New Hypertension Guidelines. Kofi Osei, MD

Modern Management of Hypertension: Where Do We Draw the Line?

Treating Hypertension from

Beta 1 Beta blockers A - Propranolol,

Adult Blood Pressure Clinician Guide June 2018

Dr Doris M. W Kinuthia

Resistant hypertension (HTN) is defined as a

Egyptian Hypertension Guidelines

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Transcription:

How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine

Definition Resistant to conventional medical therapy

Definition of Resistant Hypertension Despite intake of three or more antihypertensive drugs Resistance is usually defined as BP > 140/90 mmhg (age < 60) BP > 160/90 mmhg (age 60) Neusch et al. BMJ 2001

Definition? Resistant to conventional medical therapy 140/90 160/90 mmhg? How much doses / How many drugs?

Definition? Resistant to conventional medical therapy 140/90 160/90 mmhg? How much doses / How many drugs? Prevalance : 1-13 %?

ESH/ESC Classification Classification Optimal Normal High normal Grade 1 hypertension (mild) Grade 2 hypertension (moderate) Grade 3 hypertension (severe) Isolated systolic hypertension SBP(mmHg) < 120 120-129 130-139 140-159 160-179 180 140 DBP(mmHg) <80 80-84 85-89 90-99 100-109 110 < 90 ESH/ESC guidelines for the management of hypertension. J Hypertens, 2003

JNC-7 Classification Classification SBP(mmHg) DBP(mmHg) Normal < 120 and <80 Prehypertension Stage 1 hypertension Stage 2 hypertension 120-139 140-159 160 or 80-89 or 90-99 or 100 The JNC 7 report. JAMA 2003

Definition Resistant to conventional medical therapy JNC-7 How much doses / How many drugs?

Definition Resistant to conventional medical therapy JNC-7 How much doses / How many drugs?

Triple-drug regimen to be tried before diagnosis of resistant hypertension 1. Oral diuretics Equivalent to hydrochordthiazide 25 mg/d or Equivalent to furosemide 320mg/d, or metolazone 10 mg/d (if serum creatinine > 2.5 mg/dl)

Triple-drug regimen to be tried before diagnosis of resistant hypertension 2. Sympathetic inhibitor or Atenolol 100 mg/d or Clonidine 0.6 mg/d or Prazocin 20 mg/d or Methydopa 2 g/d ACEI (captopril 200 mg/d) or ARB (losartan 100 mg/d) or CCB (nifedipine 120 mg/d)

Triple-drug regimen to be tried before diagnosis of resistant hypertension 3. Direct vasodilator Hydralazine 100 mg/d Minoxidil 20 mg/d * In an alternative regimen, the direct vasodilator is omitted and a diuretics is used with two drugs from group 2(e.g. ACEI & CCB, or ARB & BB)

Definition Resistant to conventional medical therapy JNC-7 Three or more antihypertensive regimen

Physician-Related Factor Adequate patient education Accurate clinical diagnosis Appropriate drug therapy

Patient-Related Factor Noncompliance with treatment schedules Use of drugs that interact with antihypertensive medications Obesity and diet

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Suboptimal Therapy The most common and mostly correctable cause of resistant hypertennsion Adequate trial of maximally tolerated doses of at least three drugs; Sequential monotherapy with three drugs of different classes is not adequate Failure to prevent volume expansion with adequate diuretic therapy : one of which should be a diuretic; once the creatinine clearance falls to below 30 ml/min (scr > 2.5 mg/dl), a loop diuretic should be substituted for a thiazide congener.

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Extracellular volume expansion Most patient has relative or absolute extracellular volume expansion Underlying conditions 1) Renal insufficiency 2) Sodium retention due to vasodilators 3) Ingestion of a high salt diet 4) Presence of clinically occult expansion 5) Use of once-daily, short-acting loop diuretics Gradually removal of fluid for BP control Taler et al. Hypertension 2002

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Poor Compliance * Up to 80% are at least partially noncompliant Lack of knowledge about the disease and relative absence of symptoms Cost or side effects of medications Complex dosing schedules Burnier et al. J Hypertension 2003

Poor Compliance Check Points Patient education Rescheduling missed appointments Monitoring of drug-induced side effects Simplifying the drug regimen Monitoring of drug intake: - Pill counts - Physiologic changes after medication e.g. pulse rate for beta blockers

Life Style Modification Obesity Low salt diet Alcohol intake: limit intake to 1 oz of ethanol beer 24 oz/d, wine 8 oz/d, liquor 2 oz/d

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Secondary Hypertension Up to 11% of patients with refractory hypertension have an identifiable secondary cause. Most common are renal artery stenosis and chronic renal parenchymal disease.

Renovascular Hypertension When previously well-controlled hypertension has recently become resistant to therapy, patients older than 50 years of age with evidence of generalized vascular disease should be examined for renovascular disease. Captopril-induced renograms are useful for this purpose, unless the serum creatinine level is higher than 2 mg/dl. Doppler imaging of the renal arteries was recently shown to be sensitive in detecting radiologically confirmed renal arterial stenosis in patients with arteriosclerotic renal disease.

Primary Aldosteronism 5% of patients with refractory hypertension The aldosterone-renin ratio is useful when screening for primary aldosteronism Regardless of whether patients have an adrenal adenoma or idiopathic aldosteronism, they respond to aldosterone antagonists.

Pheochromocytoma Tests for urine metanephrines and/or catecholamines are used to screen for pheochromocytoma High-pressure liquid chromatography quantitation of metanephrines is used if there are any doubts about specificity. Endocrinologic evidence should be confirmed before proceeding to more expensive imaging techniques.

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Pickering et al. JAMA 1988 Mancia et al. Hypertension 1987 Office or White Coat HT Most patients are anxious when visiting physician; Acute rise in BP; 20 to 30 % of patients Can be minimized by having a nurse or technician take the pressure rather than the physician Development of hypotensive symptoms (weakness, dizziness) on a variety of different antihypertensive medications

Office or White Coat HT 24 hour ambulatory BP monitoring - Normal BP at work or home - Refractory office HT without end-organ damage (such as LVH on Echo) - Symptoms of hypoperfusion despite persistent hypertension Redon et al. Hypertension 1998

24h BP Monitoring Prognostic Value Refractory HT defined as Despite therapy with drugs 3 Diastolic BP 100 mmhg on 24h BP Mean 24 h D-BP vs. CV events (median 49 months) 1) < 88mmHg 2) 88-97 mmhg 3) > 97 mmhg ------- poor prognosis Redon et al. Hypertension 1998

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Pseudohypertension Old patients - thickened, calcified arteries Compression of the brachial artery with a sphygmomanometer requires a cuff pressure greater than is present within the artery Pseudohypertension: S-BP & D-BP estimated from the sphygmomanometer may be considerably higher (> 10-15 mmhg) than the directly measured intraarterial pressure Tsapatsaris, et al. Arch Intern Med 1991

Pseudohypertension Conditions suspicious of pseudohypertension: 1) Marked cuff HT without end-organ damage 2) HT medication induces hypotensive symptoms without excessive reduction in BP 3) Pipestem calcification: brachial arteries on X-ray 4) Brachial BP is higher than lower extremity BP 5) Marked isolated systolic hypertension Pseudohypertension is diagnosed as high as 30 % Zweifler, et al. J Hypertens 1993

Pseudohypertension Confirmative diagnosis of pseudohypertension by direct measurement of the intraarterial pressure Osler's maneuver - Palpating radial arterial wall after collapsing with inflation of sphygmomanometer - Poor reproducibility & interobserver variability Tsapatsaris, et al. Arch Intern Med 1991

Cuff-Inflation Hypertension Neurogenic-mediated increase in BP as the sphygmomanometer cuff is being inflated It can be diagnosed only by comparing the directly measured intraarterial diastolic pressure Why it occurs in only a few patients is not known Kugler, et al. J Hypertens 1994

Cuff-Inflation Hypertension Can also be induced by the muscular activity associated with inflating the cuff when the patient takes his or her own BP Veerman, et al. Lancet 1990

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Ingestion of Vasoactive Substance Exogenous substances can raise the BP In some cases, reduce the response to HT drugs Setaro, et al. N Engl J Med 1992

Commonly used medications and other substances that may interfere with blood pressure control Nonsteroidal anti-inflammatory drugs Over-the-counter nasal sprays, oral decongestants, and appetite suppressants containing vasoactive compounds Estrogen-containg oral contraceptives Cholestyramine: decreases absorption of diuretics Rifampin: increases clearance of propranolol Aspirin: increases clearance of captopril Tricyclic antidepressant

Commonly used medications and other substances that may interfere with blood pressure control Cyclosporin Erythropoietin Anabolic steroid, corticosteroid Recreational drugs or illicit substance Amphetamines Cocaine Cigarettes: increases metabolism of propranolol Alcohol: consumption of more than 1 oz of ethanol has direct pressor effect that may lessen benefit of antihypertensive agent

Etiology of Resistant hypertension Suboptimal therapy Extracellular volume expansion Poor compliance with medical or dietary therapy Secondary hypertension Office or "white coat" hypertension Pseudohypertension Ingestion of substances that can elevate the BP Side effects on many antihypertensive drugs Yakovlevitch, et al. Arch Intern Med 1991

Compensatory physiologic mechanisms and other causes of poor response to various antihypertensive medications Medication Cause of poor response Diuretics Excessive salt intake Overdiuresis activating of RAA Failure to use loop diuretics when creatinine clearance < 30 ml/min

Compensatory physiologic mechanisms and other causes of poor response to various antihypertensive medications Medication Cause of poor response Adrenergic Salt and water retension Blocker Beta blocker causing unopposed alpha receptor activity and increased peripheral resistance Rebound hypertension with sudden discontinuation of alpha blocker

Compensatory physiologic mechanisms and other causes of poor response to various antihypertensive medications Medication Cause of poor response ACEI Salt and water retention Hyperreninemia leading to increased production of angiotensin I

Compensatory physiologic mechanisms and other causes of poor response to various antihypertensive medications Medication Cause of poor response Direct Salt and water retension Vasodilator Reflex sympathetic stimulation Hyperreninemia

Algorithm for resistant hypertension Difficult to control Blood pressure Inaccurate Measurement Or clues for white- Coat hypertension Any antagonising Substances, such As NSAIDs or Amphetamines? Any aggravating Conditions, such As obesity or Sleep apnea Any problems With adherence? Inappropriate Medication Regimen? No Yes Yes Confirmed with Home or ambulatory Blood pressure Monitoring? White coat hypertension not Confirmed but still likely? No Work with patient to identify preferred And feasible solution Controlled blood pressure? Yes No Any common cause Of secondary hypertension, Such as renovascular or renal Parenchymal disease? No No Consider referral for further evaluation

Physicians should ask themselves. Is the patient's blood pressure really elevated? Would home monitoring help? What is the extent of target-organ damage? Is the medical regimen appropriate? Have I added a diuretic? Is the patient adhering to the regimen? Can I help the patient be more compliant? What has happened to lifestyle modifications? What is the patient's sodium intake? Is there a secondary cause of hypertension that has not been excluded?

Summary With appropriate evaluation of both patient- and physician-related factors, many cases of resistant hypertension can be resolved. Patients often do not understand the implications of their disease and need specific information regarding the importance of compliance with medication schedules and dietary restrictions. Physicians should also consider the possibility of drug resistance or the presence of an identifiable secondary cause.

Persistent Refractory HT Minoxidil (2.5 to 20 mg, twice daily) is often effective The diuretic dose usually must be increased to prevent fluid retention Sympathetic or ß-blocker also must be taken to minimize reflex sympathetic activation